Health Care [ 6/12 ] | Life Sciences Tools & Services [ 58/74 ]
NASDAQ | Common Stock
Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies.
It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma.
The company is headquartered in New York, New York.
Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 17, 25 | -0.09 Decreased by -180.54% | - |
| Dec 30, 24 | -0.31 Decreased by -1.83 K% | - |
| Aug 28, 24 | 0.04 Decreased by -44.59% | - |
| Mar 31, 24 | 0.07 Increased by +8.55% | - |
| Dec 31, 23 | 0.12 Increased by +173.93% | - |
| Sep 30, 23 | 0.02 | - |
| Jun 30, 23 | 0.07 | - |
| Mar 31, 23 | 0.07 | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 0.00 Decreased by N/A% | -6.66 M Decreased by -40.86% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | N/A - | N/A - | - - |
| Jun 30, 24 | N/A - | N/A - | - - |
| Mar 31, 24 | N/A - | N/A - | - - |
| Dec 31, 23 | 0.00 - | -4.73 M - | Decreased by N/A% - |